A citation-based method for searching scientific literature

M Monami, I Dicembrini, E Mannucci. Diabetes Obes Metab 2014
Times Cited: 66







List of co-cited articles
1078 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
62

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
57

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Michael Elashoff, Aleksey V Matveyenko, Belinda Gier, Robert Elashoff, Peter C Butler. Gastroenterology 2011
536
51

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
Sonal Singh, Hsien-Yen Chang, Thomas M Richards, Jonathan P Weiner, Jeanne M Clark, Jodi B Segal. JAMA Intern Med 2013
255
39

Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
Amy G Egan, Eberhard Blind, Kristina Dunder, Pieter A de Graeff, B Timothy Hummer, Todd Bourcier, Curtis Rosebraugh. N Engl J Med 2014
316
36

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Ling Li, Jiantong Shen, Malgorzata M Bala, Jason W Busse, Shanil Ebrahim, Per Olav Vandvik, Lorena P Rios, German Malaga, Evelyn Wong, Zahra Sohani,[...]. BMJ 2014
140
34

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
30


A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?
Peter C Butler, Michael Elashoff, Robert Elashoff, Edwin A M Gale. Diabetes Care 2013
192
24


Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.
Jean-Luc Faillie, Laurent Azoulay, Valerie Patenaude, Dominique Hillaire-Buys, Samy Suissa. BMJ 2014
56
26

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2012
21


Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study.
Carlo B Giorda, Roberta Picariello, Elisa Nada, Barbara Tartaglino, Lisa Marafetti, Giuseppe Costa, Roberto Gnavi. Lancet Diabetes Endocrinol 2014
33
39

Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population.
John A Romley, Dana P Goldman, Matthew Solomon, Daniel McFadden, Anne L Peters. Diabetes Technol Ther 2012
62
20

Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
Matteo Monami, Ilaria Dicembrini, Camilla Nardini, Irene Fiordelli, Edoardo Mannucci. Diabetes Res Clin Pract 2014
55
23

A cohort study of acute pancreatitis in relation to exenatide use.
D D Dore, G L Bloomgren, M Wenten, C Hoffman, C R Clifford, S G Quinn, D K Braun, R A Noel, J D Seeger. Diabetes Obes Metab 2011
114
18

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.
M Wenten, J A Gaebler, M Hussein, E M Pelletier, D B Smith, P Girase, R A Noel, D K Braun, G L Bloomgren. Diabet Med 2012
66
18


Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin.
Aleksey V Matveyenko, Sarah Dry, Heather I Cox, Artemis Moshtaghian, Tatyana Gurlo, Ryan Galasso, Alexandra E Butler, Peter C Butler. Diabetes 2009
183
16


Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
Jean-Luc Faillie, Samy Babai, Sabrina Crépin, Virginie Bres, Marie-Laure Laroche, Hervé Le Louet, Pierre Petit, Jean-Louis Montastruc, Dominique Hillaire-Buys. Acta Diabetol 2014
51
21



Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas.
J S Nachnani, D G Bulchandani, A Nookala, B Herndon, A Molteni, P Pandya, R Taylor, T Quinn, L Weide, L M Alba. Diabetologia 2010
139
15

A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
Carlos Alves, Francisco Batel-Marques, Ana F Macedo. Diabetes Res Clin Pract 2012
102
15

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.
Matteo Monami, Ilaria Dicembrini, Daniele Martelli, Edoardo Mannucci. Curr Med Res Opin 2011
155
15




Risk of pancreatitis in patients treated with incretin-based therapies.
Juris J Meier, Michael A Nauck. Diabetologia 2014
67
15

Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study.
Reimar Wernich Thomsen, Lars Pedersen, Niels Møller, Johnny Kahlert, Henning Beck-Nielsen, Henrik Toft Sørensen. Diabetes Care 2015
56
17

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
Baptist Gallwitz, Julio Rosenstock, Thomas Rauch, Sudipta Bhattacharya, Sanjay Patel, Maximilian von Eynatten, Klaus A Dugi, Hans-Juergen Woerle. Lancet 2012
254
13



Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.
M Gokhale, J B Buse, C L Gray, V Pate, M A Marquis, T Stürmer. Diabetes Obes Metab 2014
52
17

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Faiez Zannad, Christopher P Cannon, William C Cushman, George L Bakris, Venu Menon, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer, Craig Wilson,[...]. Lancet 2015
473
13

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
13

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
13

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia.
J Rosenstock, M S Rendell, J L Gross, P R Fleck, C A Wilson, Q Mekki. Diabetes Obes Metab 2009
144
12


The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.
Niels C B Nyborg, Anne-Marie Mølck, Lars W Madsen, Lotte Bjerre Knudsen. Diabetes 2012
103
12

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes.
C J Girman, T D Kou, B Cai, C M Alexander, E A O'Neill, D E Williams-Herman, L Katz. Diabetes Obes Metab 2010
125
12

Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study.
Antonio Gonzalez-Perez, Raymond G Schlienger, Luis A García Rodríguez. Diabetes Care 2010
91
12


Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Steven E Kahn, Steven M Haffner, Mark A Heise, William H Herman, Rury R Holman, Nigel P Jones, Barbara G Kravitz, John M Lachin, M Colleen O'Neill, Bernard Zinman,[...]. N Engl J Med 2006
10

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A Dormandy, Bernard Charbonnel, David J A Eckland, Erland Erdmann, Massimo Massi-Benedetti, Ian K Moules, Allan M Skene, Meng H Tan, Pierre J Lefèbvre, Gordon D Murray,[...]. Lancet 2005
10


Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
Priscilla L Hollander, Jia Li, Robert Frederich, Elsie Allen, Roland Chen. Diab Vasc Dis Res 2011
52
13

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents.
Krystyna Tatarkiewicz, Pamela A Smith, Emmanuel J Sablan, Clara J Polizzi, Donald E Aumann, Christiane Villescaz, Diane M Hargrove, Bronislava R Gedulin, Melissa G W Lu, Lisa Adams,[...]. Am J Physiol Endocrinol Metab 2010
77
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.